<DOC>
	<DOCNO>NCT00004058</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : This phase I trial study side effect best dose 12-O-tetradecanoylphorbol-13-acetate treating patient hematologic cancer bone marrow disorder respond previous treatment .</brief_summary>
	<brief_title>12-O-Tetradecanoylphorbol-13-acetate Treating Patients With Hematologic Cancer Bone Marrow Disorder</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose dose limit toxicity 12-O-tetradecanoylphorbol-13-acetate ( TPA ) patient relapse refractory hematologic malignancy bone marrow disorder . - Determine pharmacokinetics TPA patient . - Determine effect TPA cellular composition blood bone marrow patient . OUTLINE : This dose-escalation study . Patients receive 12-O-tetradecanoylphorbol-13-acetate ( TPA ) IV 1 hour day 1 8 follow 2 week rest . Courses repeat absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos TPA maximum tolerate dose ( MTD ) determine . The MTD define dose 1 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : Approximately 36 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven relapsed refractory hematologic malignancy bone marrow disorder standard curative therapy , include , limited : Myelodysplasia Multiple myeloma Myeloproliferative syndrome Chronic lymphocytic leukemia Aplastic anemia NonHodgkin 's lymphoma Acute leukemia Hodgkin 's lymphoma Chronic myelogenous leukemia PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : Greater 1 month Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST great 3 time ULN Renal : Creatinine great 2.0 mg/dL Cardiovascular : Cardiac ejection fraction great 40 % Pulmonary : FEV_1 great 50 % predict Other : No active infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 10 week study participation No uncontrolled psychiatric medical illness PRIOR CONCURRENT THERAPY : Biologic therapy : Greater 3 week since prior biologic therapy Chemotherapy : Greater 3 week since prior chemotherapy recover Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>primary central nervous system lymphoma</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>